Elacestrant Impresses in EMERALD Trial of Breast Cancer

$ 12.00

4.5 (417) In stock

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? - ScienceDirect

ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial

EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

May 30 - June 3, 2014 Chicago, Illinois - ppt download

EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer

Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post

Pipeline Report 2022: Patient experience takes center stage

Hobart police news

Paolo Tarantino on X: EMERALD trial: significant, albeit modest PFS improvement with elacestrant vs AI/fulvestrant in ET-pretreated MBC patients Good tolerability for elacestrant, with main AE being nausea. Could become the first

Lorenzo Gerratana on X: First results of the EMERALD trial: single agent # elacestrant is a promising new endocrine option, #biomarkers are needed for a real #personalized treatment there is a rapidly progressive